Drug Delivery
Creative Biolabs Enhances Gene Therapy Research with Expanded Liposomal Drug Delivery Services
Creative Biolabs has expanded its liposomal drug delivery services to support advancements in gene therapy, oncology, and molecular medicine, offering customized solutions for research institutions and pharmaceutical industries worldwide.
Oragenics Inc. Advances Toward Phase IIa Concussion Trial with ONP-002
Oragenics Inc. (NYSE American: OGEN) is making significant progress with its lead candidate, ONP-002, aiming to become the first FDA-approved pharmacological treatment for concussion, highlighting the potential of its intranasal delivery technology in transforming neurological care.
Branded Legacy, Inc. to Acquire Bio-Legacy Evaluative Group, Expanding into Intranasal Drug Delivery Market
Branded Legacy, Inc. (OTC: BLEG) has signed a Letter of Intent to acquire Bio-Legacy Evaluative Group, marking a strategic expansion into the intranasal drug delivery sector with a focus on addiction treatments and vaccine accessibility.
Lexaria's DehydraTECH-Semaglutide Shows Promising Reduction in Side Effects Compared to Rybelsus®
Lexaria Bioscience Corp. reports interim results from its Phase 1b study, showing DehydraTECH-semaglutide significantly reduces gastrointestinal and overall side effects compared to Rybelsus®, potentially improving patient adherence to treatment.
Creative Biolabs Enhances Drug Delivery with LipoDrive™ Platform
Creative Biolabs introduces the LipoDrive™ platform, a cutting-edge solution for liposomal drug delivery, addressing the growing demand for precision in biopharmaceutical formulations.
Medicus Pharma Ltd. Develops Novel Non-Invasive Treatment for Basal Cell Carcinoma
Medicus Pharma Ltd. is advancing a revolutionary, non-invasive microneedle patch treatment for basal cell carcinoma, potentially transforming the $15 billion skin cancer treatment market.
Molecular 'Velcro' Breakthrough Promises Advanced Drug Delivery and Biosensing Technologies
Researchers introduce a novel supramolecular chemistry concept called controllable ultrahigh-affinity molecular recognition (CUAMR), which offers unprecedented control in molecular interactions with potential transformative applications in biotechnology and medicine.
Creative Biolabs Advances Antibody-Drug Conjugate Technology with Innovative Engineering Techniques
Creative Biolabs has made significant breakthroughs in antibody-drug conjugate (ADC) development, demonstrating advanced glycosylation engineering and innovative approaches to targeting cancer treatments through bispecific and antibody-oligonucleotide conjugates.
Breakthrough Supramolecular Bakuchiol Offers Gentle, Effective Anti-Aging Solution
Researchers develop a novel supramolecular delivery system for bakuchiol that significantly enhances skin penetration and anti-aging effects while minimizing irritation, potentially transforming the skincare industry.
Creative Biolabs Advances Antibody Technologies to Revolutionize Cancer Treatment
Creative Biolabs is expanding its innovative antibody-related technologies, targeting critical advancements in cancer research and immunotherapy. The company's platforms aim to enhance drug delivery precision and improve therapeutic strategies for previously challenging medical conditions.
Creative Biolabs Advances Drug Delivery with Custom Emulsion Technology
Creative Biolabs has developed innovative emulsion formulations designed to enhance drug stability and bioavailability, offering customized solutions for challenging pharmaceutical delivery systems. The breakthrough technology addresses critical drug solubility issues across various pharmaceutical applications.
Nutriband CEO Gareth Sheridan Named EY Entrepreneur of the Year 2025 Finalist
Nutriband's CEO Gareth Sheridan has been recognized as a finalist in the EY Entrepreneur of the Year Awards, highlighting the company's innovative work in transdermal drug delivery and abuse-deterrent technologies.